{"filings":[{"id":1056482,"accession_number":"0001104659-26-074025","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2026-06-15T20:05:42+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Milestone Pharma shareholders approve 6.8M share increase to equity plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved 2019 Equity Plan amendment to increase authorized shares by 6,800,000.","All seven director nominees elected; votes for ranged from 23.4M to 24.2M.","Ratification of PricewaterhouseCoopers as auditor: 75,025,285 for, 249,836 against.","Advisory vote on executive compensation passed: 19,665,705 for, 6,990,920 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50081,"accession_number":"0001104659-26-059780","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2026-05-13T11:23:09+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone Q1 2026 net loss $26.1M; CARDAMYST launch yields $0.2M revenue, 600 scripts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue of $0.2M from first quarter of CARDAMYST launch; no prior-year revenue.","Net loss $26.1M ($0.20 per share) vs $20.8M ($0.31) a year ago; cash $184.2M, runway into H2 2027.","~600 scripts filled for 560 PSVT patients; ~400 unique prescribers as of April.","Express Scripts national formulary coverage effective March 27, 2026; >25% of commercially insured lives covered.","Phase 3 AFib-RVR trial initiated; first patient enrollment expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":238000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103694,"accession_number":"0001104659-26-032427","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone Pharma FY2025 net loss $63.1M; CARDAMYST launch on track; cash runway into late 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $63.1M ($0.75 per share) for FY2025 vs $41.5M ($0.67) prior year.","Revenue of $1.5M from CARDAMYST FDA approval milestone under Corxel agreement.","Commercial expense $28.3M for FY2025; 60-person sales force deployed mid-Feb.","Pro forma cash $200M including $75M RTW payment and $19M ATM/warrant exercises; runway to late 2027.","EMA accepted MAA for etripamil; decision expected H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103693,"accession_number":"0001104659-26-006483","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Milestone launches CARDAMYST nasal spray for PSVT via U.S. retail pharmacies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CARDAMYST (etripamil) is now available through U.S. retail pharmacies as first self-administered PSVT treatment.","National sales force deployment set for mid-February 2026 to support commercialization.","Eligible commercially insured patients receive a $25 copay cap via patient assistance program.","FDA approved CARDAMYST on December 12, 2025 — first PSVT therapy approved in over 30 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103692,"accession_number":"0001104659-26-003038","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Milestone closes $75M royalty sale to RTW for etripamil US net sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed sale of royalty interest under Royalty Purchase Agreement with RTW Royalty I DAC.","Received $75 million purchase price from funds managed by RTW.","Royalty interest is on annual net product sales of etripamil in the United States.","Previously disclosed on March 27, 2023; FDA approval of etripamil a condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103691,"accession_number":"0001104659-26-001099","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Milestone Pharma announces EMA acceptance of MAA for etripamil in PSVT; decision expected Q1 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EMA accepted Marketing Authorization Application for etripamil nasal spray (TACHYMIST) for PSVT; decision expected Q1 2027.","Phase 3 RAPID trial: 64% conversion to sinus rhythm at 30 min vs 31% placebo (p<0.001); median time 17 min vs 54 min.","Drug is conditionally approved brand name TACHYMIST in Europe; ~2 million PSVT patients in Europe.","MAA includes global clinical data that supported U.S. FDA approval of etripamil for PSVT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119949,"accession_number":"0001104659-25-120904","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Milestone receives FDA approval for CARDAMYST (etripamil) nasal spray for PSVT","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved CARDAMYST (etripamil) on Dec 12, 2025 for self-administration in adults with PSVT; first new treatment in 30+ years.","Phase 3 RAPID: 64% converted to sinus rhythm within 30 min vs 31% placebo (HR=2.62, p<0.001); median time 17 min vs 54 min.","Product expected in retail pharmacies Q1 2026; company well-capitalized for launch with existing capital and royalty financing.","FDA approval enables AFib-RVR development under sNDA pathway; Phase 3 program planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119948,"accession_number":"0001104659-25-109744","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone reports Q3 net loss $11.9M; PDUFA target Dec 13 for CARDAMYST in PSVT","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and short-term investments $82.6M at Sept 30, up from $69.7M at Dec 31, 2024.","Net loss Q3 $11.9M vs $9.4M a year ago; no revenue reported in either period.","Commercial expense surged to $4.6M (Q3) from $1.9M on launch prep for potential FDA approval.","NDA for CARDAMYST (etripamil) under FDA review; PDUFA action date December 13, 2025.","Completed $48.7M equity offering and amended Royalty Purchase Agreement securing $75M upon approval."],"consensus_eps_estimate":-0.1673,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136517,"accession_number":"0001104659-25-076468","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone Pharma: FDA accepts CRL response for CARDAMYST; new Dec 13 PDUFA date; Q2 net loss $13M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted CRL response for CARDAMYST (etripamil) for PSVT; new PDUFA target Dec 13, 2025.","Completed public equity offering in July, raising up to $170M gross if warrants exercised; net proceeds ~$48.7M.","Amended royalty agreement with RTW, extending approval deadline to Dec 31, 2025 for up to $75M payment.","Cash, cash equivalents and short-term investments $43.4M as of June 30; net loss $13M for Q2 vs $9.4M Q2 2024.","Commercial expense increased to $5.1M in Q2 (vs $1.8M) as company maintains launch capability pending approval."],"consensus_eps_estimate":-0.1811,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136516,"accession_number":"0001104659-25-067579","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Milestone Pharmaceuticals prices $52.5M public offering of common shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced $52.5M offering of 31.5M common shares + Series A and B warrants at $1.50/unit; 3.5M pre-funded warrants at $1.499/unit.","Net proceeds expected ~$48.7M after underwriting commissions and expenses.","Series A warrants exercisable at $1.50 for 1 year; Series B at $1.875 for 5 years, with mandatory exercise trigger at $3.50 VWAP.","Proceeds to fund etripamil clinical development and commercial launch for paroxysmal supraventricular tachycardia (PSVT).","Offering led by TD Cowen, Piper Sandler, Wells Fargo; expected to close July 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136515,"accession_number":"0001104659-25-067108","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"FDA accepts Milestone's CRL response for CARDAMYST; new PDUFA Dec 13, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted Milestone's response to CRL for CARDAMYST (etripamil) nasal spray for PSVT; new PDUFA target date Dec 13, 2025.","$75M Royalty Purchase Agreement with RTW extended; approval deadline moved from Sept 30, 2025 to Dec 31, 2025.","CRL response submitted June 13, 2025 after FDA Type A meeting; included additional nitrosamine studies and facility transfer.","FDA raised no concerns regarding clinical section of NDA.","RTW proceeds expected to aid CARDAMYST commercial launch if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153689,"accession_number":"0001104659-25-059671","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Milestone submits CRL response for CARDAMYST (etripamil) PSVT NDA after Type A meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted CRL response to FDA on June 16, 2025, following a productive Type A meeting.","FDA will determine acceptance and set PDUFA date within 30 days.","Review timeline expected to be 2 or 6 months depending on classification.","CARDAMYST, if approved, would be the first self-administered therapy for acute PSVT episodes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153688,"accession_number":"0001104659-25-058874","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve 2019 EIP amendment, increase share pool by 4M; directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal to amend 2019 EIP to remove evergreen provision and add 4,000,000 shares approved (8.04M for, 4.74M against, 14.9M broker non-votes).","All eight director nominees elected: Joseph Oliveto, Stuart Duty, Seth Fischer, Lisa Giles, Joseph Papa, Andrew Saik, Michael Tomsicek, Robert Wills.","Ratification of PwC as auditor passed with 28.1M for, 284k against, 159k abstentions.","Non-binding advisory vote on executive compensation (9.2M for, 3.6M against) and triennial frequency (12.3M for 1-year) passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153687,"accession_number":"0001104659-25-048160","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone Pharma Q1 net loss $20.8M; CRL issues unresolved; Type A meeting requested","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $20.8M vs $10.4M YoY; no revenue; cash $56.0M down from $69.7M.","FDA CRL for CARDAMYST (etripamil) in PSVT cites nitrosamine impurities and facility GMP issues.","Type A meeting requested with FDA to address CMC concerns; no clinical safety/efficacy issues.","New USPTO method-of-use patent extends etripamil IP protection to July 2042.","Phase 3 AFib-RVR enrollment paused to prioritize CRL resolution; commercial ramp temporarily halted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172385,"accession_number":"0001104659-25-029047","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for etripamil PSVT NDA; no clinical issues raised","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CRL focuses on CMC: additional nitrosamine impurity data and facility inspection required.","No clinical safety or efficacy concerns cited by FDA for CARDAMYST (etripamil) nasal spray.","Company plans to request a Type A meeting with FDA to discuss resubmission path.","Cash, cash equivalents and short-term investments of $69.7M as of Dec 31, 2024.","CEO expresses disappointment but remains committed to the program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172384,"accession_number":"0001104659-25-025547","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Milestone Pharmaceuticals sets June 10, 2025 as annual meeting date; record date April 15","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2025 annual meeting scheduled for June 10, 2025; record date for voting is April 15, 2025.","Shareholder proposals under Rule 14a-8 must be received by the company secretary by March 29, 2025.","Proposals under Quebec Business Corporations Act and company by-laws due by April 15, 2025.","Universal proxy rule notice for director nominations must be provided by April 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172383,"accession_number":"0001104659-25-025055","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Milestone Pharmaceuticals amends ATM sales agreement with Jefferies to up to $77.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended Open Market Sale Agreement replaces prior $50M facility; total capacity increased to $77.8M including ~$2.8M already sold.","Common shares sold at-the-market via Jefferies; company pays 3.0% commission on gross proceeds.","Prospectus supplement to be filed under existing S-3 shelf registration (File No. 333-283162).","Company not obligated to sell any shares; agreement may be terminated early by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172382,"accession_number":"0001104659-25-023218","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone reports Q4 2024 net loss $12.4M; FDA PDUFA date for CARDAMYST is March 27, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA PDUFA goal date for CARDAMYST (etripamil) in PSVT is March 27, 2025; launch targeted for mid-2025 if approved.","Cash, cash equivalents, and short-term investments: $69.7M as of Dec 31, 2024, vs $66.0M year-end 2023.","Q4 2024 net loss $12.4M ($0.19/share), improved from $13.6M ($0.32/share) in Q4 2023.","Full year 2024 net loss $41.5M ($0.67/share), vs $59.7M ($1.39/share) in 2023; revenue zero.","Phase 3 trial for etripamil in AFib-RVR on track to initiate in 2025 with patient self-administration regimen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172381,"accession_number":"0001104659-25-016929","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Milestone Pharma provides corporate presentation ahead of March 27 PDUFA for CARDAMYST","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA for CARDAMYST (etripamil) nasal spray remains under FDA review with PDUFA date of March 27, 2025.","Presentation outlines potential commercial launch strategy, but product is not yet approved.","Company actively preparing for launch pending FDA decision.","Presentation used at investor meetings; available on company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189388,"accession_number":"0001104659-24-116493","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone reports Q3 net loss of $9.4M; PDUFA for CARDAMYST set for March 27, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PDUFA target date for CARDAMYST (etripamil) in PSVT is March 27, 2025.","China Phase 3 met primary endpoint: 40.5% conversion vs 15.9% placebo within 30 min (HR=3.00, p<0.001).","Phase 3 trial in AFib-RVR expected to start H1 2025 with repeat-dose 70 mg regimen.","Cash, equivalents and short-term investments $76.4M at Sep 30, 2024, up from $66.0M at Dec 31, 2023.","Net loss narrowed to $9.4M in Q3 2024 vs $15.1M in Q3 2023; R&D expense $4.0M vs $6.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205884,"accession_number":"0001104659-24-096648","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Milestone Pharmaceuticals appoints Joseph Papa to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Papa, CEO of Emergent BioSolutions, appointed director effective Sept 3, 2024; over 35 years pharma experience.","Papa will serve on Compensation Committee; receives $42,500 annual cash retainer and 80,000-share option grant.","2024 annual meeting results: all 7 director nominees elected; PricewaterhouseCoopers ratified as auditor.","Board committees updated: Fischer named Compensation Chair; Papa joins Compensation Committee.","Company advancing CARDAMYST (etripamil nasal spray) for PSVT towards potential FDA decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205883,"accession_number":"0001104659-24-087301","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone Q2 net loss $9.4M; FDA acceptance of CARDAMYST NDA with PDUFA March 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted CARDAMYST (etripamil) NDA for PSVT; PDUFA target date set for March 2025.","Cash and equivalents $83.3M as of June 30, 2024, expected to fund operations into 2026.","Q2 2024 net loss $9.4M vs $16.0M in Q2 2023; R&D expenses down to $2.8M from $8.6M.","Stuart Duty and Andrew Saik appointed as independent directors to the board.","Phase 3 AFib-RVR trial design ongoing; enrollment planned for first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205882,"accession_number":"0001104659-24-079854","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["1.01","5.02","5.08","8.01","9.01"],"status":"ready","headline":"Milestone adds two directors, plans third under agreement with Alta activist investor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Stuart Duty and Andrew Saik as independent directors effective July 14, 2024.","Cooperation agreement: Alta withdraws director nominations; Milestone to appoint third mutually agreeable independent by Sept 6, 2024.","Directors Debra Liebert and Richard Pasternak will not stand for reelection (no disagreement).","Alta agrees to standstill and vote with board recommendations until after 2025 annual meeting.","Board size to rise to nine then reduce to eight after 2024 meeting and third appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222892,"accession_number":"0001104659-24-065806","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Milestone Pharma gets FDA NDA acceptance for CARDAMYST (etripamil) nasal spray for PSVT","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA on May 26, 2024 for CARDAMYST (etripamil) nasal spray for paroxysmal supraventricular tachycardia (PSVT).","PDUFA target date set at 10 months from acceptance (approx. March 2025).","CEO Joseph Oliveto cites progress toward a new self-administered treatment option for PSVT patients.","CARDAMYST clinical program represents the largest data package ever studied for acute self-management of PSVT.","Brand name CARDAMYST is conditionally approved by FDA; commercial preparations continue for potential launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222891,"accession_number":"0001104659-24-060221","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone restarts PSVT NDA for etripamil; cash of $89.5M funds into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["NDA for etripamil in PSVT resubmitted after FDA Type A meeting; standard review expected, potential approval in H1 2025.","Cash, equivalents and short-term investments of $89.5M as of March 31, 2024, expected to fund operations into 2026.","No revenue in Q1 2024 vs $1.0M in Q1 2023; net loss of $10.4M improved from $15.0M a year ago.","R&D expense fell to $3.6M from $10.3M due to completion of Phase 3 PSVT studies.","March 2024 public offering of common shares and pre-funded warrants raised net proceeds of ~$32.2M for development and commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222890,"accession_number":"0001104659-24-044767","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Milestone Pharma reports positive Phase 3 etripamil data for PSVT self-treatment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NODE-303 open-label study: etripamil nasal spray restored sinus rhythm with median time-to-conversion 17.0 minutes.","Efficacy at 30 min was 60%, at 60 min 69.9% — similar to prior double-blinded studies.","Safety consistent: adverse events mostly localized to nasal administration site; frequency decreased with successive episodes.","Data presented at ACC 2024 and published in JACC; supports potential shift in PSVT self-management.","CARDAMYST (conditionally approved brand name) could become first at-the-ready option for acute PSVT if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242362,"accession_number":"0001104659-24-040008","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Milestone Pharmaceuticals resubmits NDA for etripamil nasal spray to FDA for PSVT","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA resubmission for self-administered etripamil nasal spray to treat paroxysmal supraventricular tachycardia (PSVT).","Resubmission follows FDA Type A meeting after a Refusal to File letter; no new efficacy/safety data requested.","Package includes restructured AE timing data and reformatted data files to facilitate FDA review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242361,"accession_number":"0001104659-24-036941","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone Pharma reports Q4 net loss of $13.6M; on track to resubmit NDA for etripamil in PSVT early Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.6M in Q4 2023, full year net loss $59.7M; Q4 revenue was $0 (vs $3.5M in Q4 2022).","Cash and equivalents $66M as of Dec 31, 2023; March 2024 offering raised ~$32.4M net, extending cash runway into 2026.","Plans to resubmit NDA for etripamil in PSVT early Q2 2024 after Type A meeting with FDA resolved RTF items.","FDA reiterated guidance for AFib-RVR Phase 3 pathway contingent on PSVT NDA approval; End of Phase 2 meeting expected mid-2024.","R&D expense fell to $5.5M in Q4 (vs $10.6M) as Phase 3 studies completed; commercial expense rose to $5.0M (vs $2.6M) for launch prep."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242360,"accession_number":"0001104659-24-030267","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Milestone Pharmaceuticals prices $30M public offering; net proceeds ~$32.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 16,666,667 common shares at $1.50/share and 3,333,333 pre-funded warrants at $1.499/warrant.","Underwriters' option for 3,000,000 additional common shares exercised in full.","Net proceeds of ~$32.4M to fund etripamil development for PSVT and AFib-RVR, plus working capital.","Expected to close on or about March 4, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242359,"accession_number":"0001104659-24-027262","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Milestone Pharma plans to resubmit NDA for etripamil in 2Q2024 after FDA Type A meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA indicated that timing of adverse events had minimal impact on overall etripamil safety profile.","No additional clinical efficacy or safety trials required before NDA resubmission; standard review expected.","NDA resubmission for paroxysmal supraventricular tachycardia (PSVT) planned for 2Q2024.","Cash conservation measures extend operating runway into mid-2025, covering expected PDUFA date.","Upon FDA approval, Milestone would receive a $75M payment under an existing royalty agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259754,"accession_number":"0001104659-23-128988","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2023-12-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Milestone Pharma receives FDA refusal to file for etripamil NDA for PSVT","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued Refusal to File letter for etripamil NDA submitted October 2023.","FDA cited insufficient completeness, requested clarification on adverse event timing in Phase 3.","FDA did not express concerns about nature or severity of adverse events.","Milestone will seek meeting with FDA to address issues and agree on path forward.","Etripamil is a self-administered nasal spray for paroxysmal supraventricular tachycardia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259753,"accession_number":"0001104659-23-116646","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone Pharma reports Q3 2023 results; NDA submitted for etripamil in PSVT","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $75.7M as of Sep 30, 2023; expected to fund operations into mid-2025.","Q3 operating loss $15.4M vs $15.0M prior year; R&D expense down to $6.7M.","NDA for etripamil (CARDAMYST) in PSVT submitted to FDA; acceptance decision by end of 2023.","Positive Phase 2 ReVeRA data for etripamil in AFib-RVR presented at AHA; Phase 3 program to start mid-2024.","Commercial expense rose to $4.4M in Q3 from $2.7M prior year, building pre-launch capabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259752,"accession_number":"0001104659-23-116598","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Milestone's etripamil Phase 2 meets primary endpoint; 30 bpm ventricular rate reduction vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean ventricular rate reduction of 29.91 bpm vs placebo (p<0.0001); absolute max reduction 35 bpm etripamil vs 5 bpm placebo.","58.3% of etripamil patients achieved <100 bpm vs 4% placebo; median time to max reduction 13 min, effect ~150 min.","TSQM-9 patient-reported symptom relief significantly improved: effectiveness (p<0.0001) and relief of symptoms (p=0.0002).","Safety consistent with PSVT program; SAEs rare: one patient with transient severe bradycardia/syncope resolved.","Company plans Phase 3 trial; NDA for etripamil in PSVT already submitted with FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259751,"accession_number":"0001104659-23-115048","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Milestone to host webcast Nov 13 on etripamil Phase 2 AFib-RVR study results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Webcast on Monday Nov 13, 2023 at 8:00 a.m. ET to discuss ReVeRA Phase 2 results of etripamil in AFib-RVR.","Key opinion leaders A. John Camm, MD, and Sean Pokorney, MD, will join the webcast.","Results presented as Featured Science at AHA Scientific Sessions 2023.","Dial-in: (877) 870-4263 (domestic) or (412) 317-0790 (international).","Webcast and slides accessible via News & Events section of Milestone's IR website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259750,"accession_number":"0001104659-23-111088","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Milestone files NDA for etripamil; Phase 3 showed 2x efficacy, 3x speed vs placebo","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted NDA to FDA for etripamil (CARDAMYST) for paroxysmal supraventricular tachycardia (PSVT) on Oct 24, 2023.","Pivotal Phase 3 RAPID trial published in The Lancet; etripamil restored normal rhythm 2x more effectively and 3x faster than placebo.","FDA 60-day filing review period to determine completeness; if accepted, standard 10-month review expected.","Brand name CARDAMYST conditionally approved by FDA; commercial preparations underway for anticipated launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277041,"accession_number":"0001104659-23-089566","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone Pharma Q2 2023: cash $87.6M, NDA for etripamil due Oct 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents & short-term investments of $87.6M; runway into mid-2025.","NDA submission for etripamil nasal spray (PSVT) planned for October 2023.","Enrollment complete in Phase 2 ReVeRA trial (AFib-RVR); topline data Q4 2023.","Operating loss Q2 2023: $16.4M vs $16.8M in Q2 2022; R&D expense down to $8.6M.","Commercial expense rose to $3.4M in Q2 2023 from $2.2M a year earlier."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294898,"accession_number":"0001104659-23-069992","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Milestone Pharmaceuticals holds 2023 annual meeting; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with substantial votes for; highest withheld was Robert J. Wills with 1,317,985 withheld.","PricewaterhouseCoopers LLP appointed as auditor for the Company with 23,410,435 votes for and 41,638 withheld.","Broker non-votes ranged from 9,626,977 to 9,626,978 per director nominee.","Meeting held virtually on June 7, 2023; proposals described in proxy statement filed April 28, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294897,"accession_number":"0001104659-23-058749","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone Pharma Q1 operating loss $15M; etripamil NDA on track for Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash of $101M as of March 31, 2023; with $125M RTW financing, runway into mid-2025.","NDA submission for etripamil (PSVT) to FDA remains on track for Q3 2023.","Phase 2 ReVeRA trial (AFib-RVR) topline data expected H2 2023.","Appointed Seth H.Z. Fischer to Board of Directors in March 2023.","Operating loss of $15.0M in Q1 2023 vs. $14.0M in Q1 2022; R&D expense rose to $10.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315477,"accession_number":"0001104659-23-039764","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["2.03","3.02","7.01","9.01"],"status":"ready","headline":"Milestone Pharma raises $50M in convertible notes and $75M contingent royalty sale","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $50M principal of 6.0% Convertible Senior Notes due 2029 to RTW Investments.","Notes convertible at ~$5.23 per share (191.0548 shares per $1,000 principal).","Interest payable quarterly; PIK option for first 3 years; secured by substantially all assets.","Royalty Purchase Agreement: RTW to pay $75M for tiered royalties on U.S. etripamil sales post-FDA approval.","Proceeds support development of etripamil; notes mature March 31, 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315476,"accession_number":"0001104659-23-038073","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone reports FY2022 operating loss of $58.4M; NDA for etripamil on track for Q3 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents, and short-term investments of $64.6M as of Dec 31, 2022; plus $50M from March 2023 private placement expected to fund into mid-2025.","NDA submission for etripamil nasal spray in PSVT expected in Q3 2023; Phase 3 RAPID trial met primary endpoint (64.3% conversion vs 31.2% placebo).","Entered $125M strategic financing with RTW Investments: $50M convertible notes and $75M synthetic royalty commitment post-FDA approval.","Seth H.Z. Fischer appointed to Board of Directors effective March 21, 2023; brings commercial expertise from Johnson & Johnson and Vivus.","Full year 2022 operating loss of $58.4M vs $42.9M in 2021; R&D expense $39.8M, G&A $15.7M, commercial $9.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315475,"accession_number":"0001104659-23-037370","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Milestone Pharmaceuticals secures $125M financing from RTW for etripamil PSVT program","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$50M in 6.0% convertible senior notes due 2029, convertible at $5.23/share (50% premium over VWAP).","$75M non-dilutive synthetic royalty commitment on US net sales of etripamil, subject to FDA approval.","Combined with $64.6M year-end cash, expected to fund operations into mid-2025 including NDA submission and PSVT launch.","NDA submission for etripamil in paroxysmal supraventricular tachycardia planned for Q3 2023.","RTW receives tiered royalty rates (high to low single digits) based on annual sales thresholds; rate steps up if thresholds missed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315474,"accession_number":"0001104659-23-037189","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Milestone exchanges 1.06M shares with RTW for pre-funded warrants; adds director Fischer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 1,059,000 common shares with RTW Investments for pre-funded warrants at $0.001 exercise price, no expiration.","Warrants immediately exercisable; subject to 9.99% beneficial ownership limitation.","Seth H.Z. Fischer elected to Board, effective March 21, 2023; over 40 years pharma experience, including Johnson & Johnson.","Fischer receives $35,000 annual cash retainer and initial option for 42,000 shares vesting over 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315473,"accession_number":"0001104659-23-031319","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Milestone Pharmaceuticals confirms no deposits or accounts at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company states it does not hold any deposits or securities at Silicon Valley Bank.","No accounts maintained at SVB, addressing investor concerns after bank collapse.","Disclosure provided in March 10, 2023 Form 8-K under Item 7.01."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315472,"accession_number":"0001104659-23-029345","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Milestone Pharmaceuticals provides updated corporate presentation at Cowen Healthcare Conference","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation filed as Exhibit 99.1; no financial figures or material updates disclosed in filing body.","Company participated in Cowen Annual Health Care Conference on March 7, 2023.","Presentation available on company's investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333813,"accession_number":"0001104659-22-124907","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CSO Francis Plat to retire Dec 31; company details etripamil commercial plan with NDA in mid-2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CSO Francis Plat retires Dec 31, 2022; consulting agreement at $15k/month (Stage 1) or $300/hr (Stages 2/3).","RAPID Phase 3 data: 64% conversion at 30 min (etripamil) vs 31% placebo; median time 17 min vs 54 min.","NDA submission for etripamil in PSVT expected mid-2023; development in AFib-RVR also underway.","Initial target market 600,000–900,000 patients; net price estimate $500–$1,000/Rx; cardiologists report 53% adoption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333812,"accession_number":"0001104659-22-117099","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone reports Q3 operating loss $14.6M; Phase 3 RAPID trial meets primary efficacy endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 RAPID trial met primary endpoint: 64.3% etripamil vs 31.2% placebo conversion to sinus rhythm within 30 min (HR=2.62, p<0.001).","Additional AHA data: conversion rates ~74% at 60 min, ~80% at 90 min; median time to conversion 17.2 min for etripamil.","Company plans to submit NDA for etripamil in PSVT to FDA in mid-2023, pending agency feedback.","Cash, cash equivalents, and short-term investments $77.2M as of Sept 30, 2022; expected to fund operations through 2023.","Successful RAPID results triggered $3.5M milestone payment from partner Ji Xing; total potential milestones up to $107.5M in Greater China."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333811,"accession_number":"0001104659-22-108996","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2022-10-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Milestone Pharma announces positive Phase 3 RAPID trial results for etripamil in PSVT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: 64.3% of etripamil patients converted to sinus rhythm within 30 min vs 31.2% placebo (HR=2.62, p<0.001).","Safety profile consistent with prior trials; no serious AEs related to etripamil; majority of AEs mild (68%) to moderate (31%).","Pooled data show statistically significant reduction in medical interventions and ED visits.","Company plans to submit NDA to FDA in mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351278,"accession_number":"0001104659-22-088661","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Milestone Pharma: Phase 3 RAPID PSVT trial reaches 180 events; topline data on track for mid-H2 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 2022 operating loss $16.8M vs income $0.7M prior year due to $15M one-time revenue from Ji Xing in 2021; cash $86.2M.","RAPID Phase 3 PSVT trial achieved target of 180 confirmed events; topline data expected mid-second half 2022.","Ji Xing enrolled first patient in Phase 3 etripamil study in China; data may support NDA in China.","NODE-302 open-label extension data showed 60.2% PSVT conversion at 30 min; 8.5% ED intervention rate.","R&D expense $10.7M in Q2 2022, up from $9.4M due to RAPID trial advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351277,"accession_number":"0001104659-22-078354","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2022-07-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Milestone Pharmaceuticals shareholders elect directors, approve auditor and equity plan amendment at 2022 meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected: Joseph Oliveto, Lisa M. Giles, Richard Pasternak, Debra K. Liebert, Michael Tomsicek, Robert J. Wills. Votes for each ranged 19,105,725 – 19,110,012.","PricewaterhouseCoopers LLP appointed as auditor for 2023 with 24,809,612 votes for, 0 against, 217,072 withheld.","Amendment to 2019 Equity Incentive Plan approved; increase of 1,000,000 shares authorized. 15,462,071 for, 3,652,167 against, 5,912,446 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387865,"accession_number":"0001104659-22-037283","cik":1408443,"company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","form_type":"8-K","filed_at":"2022-03-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Milestone Pharma reports FY2021 net loss of $42.9M; revenue of $15M from collaboration","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Net loss for FY2021 was $42.9M ($1.02 loss per share) vs $50.0M ($1.70 loss per share) in FY2020.","Revenue of $15.0M recognized in 2021 from collaboration agreement; no revenue in 2020.","R&D expenses $38.7M, G&A $12.4M, commercial $7.0M in FY2021.","Cash and cash equivalents $114.1M at Dec 31, 2021, down from $142.3M (incl short-term investments) at Dec 31, 2020.","Accumulated deficit reached $206.3M as of Dec 31, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":178654596.175,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-24T23:59:59+00:00|387865"}